A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
Status: | Active, not recruiting |
---|---|
Conditions: | Lung Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 2/23/2019 |
Start Date: | May 11, 2016 |
End Date: | February 28, 2019 |
A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer
The purpose of this study is to evaluate the safety and efficacy of prexasertib when given to
participants with extensive stage disease small cell lung cancer (ED-SCLC). The study will
evaluate how the body processes the drug and how the drug affects the body. The study will
also evaluate the association between tumor response and the participant's perceived quality
of life.
participants with extensive stage disease small cell lung cancer (ED-SCLC). The study will
evaluate how the body processes the drug and how the drug affects the body. The study will
also evaluate the association between tumor response and the participant's perceived quality
of life.
Inclusion Criteria:
- Have ED-SCLC and have received a prior platinum-based regimen
- Participants in Cohort 1 and in the addendum must have had an objective response to
prior platinum-based therapy with subsequent progression ≥90 days after the last dose
of platinum
- Participants in Cohort 2 must have either not had an objective response to prior
platinum based therapy or had progression <90 days after the last dose of platinum
- Have a performance status of 0 to 1 on the Eastern Cooperative Oncology Group scale
Exclusion Criteria:
- Have received more than 2 prior therapies for ED-SCLC (including immunotherapy,
targeted therapies, or chemotherapy)
- Have symptomatic central nervous system (CNS) malignancy or metastasis. Asymptomatic
participants with treated CNS metastases are eligible for this study if they are not
currently receiving corticosteroids to treat CNS metastases
- Have previously completed or withdrawn from this study or any other study
investigating prexasertib or a checkpoint kinase I (CHK1) inhibitor or have shown
hypersensitivity to any of the components of the prexasertib formulation
- Have a serious cardiac condition
We found this trial at
15
sites
Saint Petersburg, Florida 33705
Principal Investigator: Maen Hussein
Phone: 72721611433081
Click here to add this to my saved trials
3840 Broadway
Fort Myers, Florida 33901
Fort Myers, Florida 33901
(239) 275-6400
Principal Investigator: Michael McCleod
Phone: 239-274-9930
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
Nashville, Tennessee 37232
(615) 322-5000
Principal Investigator: Leora Horn
Phone: 615-322-4967
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
Click here to add this to my saved trials
Click here to add this to my saved trials
Chattanooga, Tennessee 37404
Principal Investigator: Davey Daniel
Phone: 423-698-1844
Click here to add this to my saved trials
Click here to add this to my saved trials
Fayetteville, Arkansas 72703
Principal Investigator: Eric Schaefer
Phone: 479-587-1700
Click here to add this to my saved trials
Fort Worth, Texas 76104
Principal Investigator: Ray Page
Phone: 817-759-7023
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
Houston, Texas 77030
713-792-2121
Principal Investigator: Lauren Byers
Phone: 713-792-2848
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
Click here to add this to my saved trials
1 Medical Center Dr
Lebanon, New Hampshire 03756
Lebanon, New Hampshire 03756
(603) 650-5000
Principal Investigator: Konstantin Dragnev
Phone: 603-650-6344
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
Click here to add this to my saved trials
230 25th Ave N
Nashville, Tennessee 37203
Nashville, Tennessee 37203
(615) 329-7274
Principal Investigator: SMO Sarah Cannon Research Inst
Phone: 615-329-7274
Sarah Cannon Cancer Center People who live with cancer
Click here to add this to my saved trials
250 25th Ave N, Ste 100
Nashville, Tennessee 37023
Nashville, Tennessee 37023
615-320-5090
Principal Investigator: Melissa Johnson
Phone: 615-329-7274
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
Click here to add this to my saved trials
333 Cedar St
New Haven, Connecticut 06504
New Haven, Connecticut 06504
(203) 432-4771
Principal Investigator: Anne Chiang
Yale University School of Medicine Founded in 1810, the Yale School of Medicine is a...
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Saiama Waqar
Phone: 314-362-5817
Click here to add this to my saved trials
3800 Reservoir Rd NW
Washington, District of Columbia 20007
Washington, District of Columbia 20007
(202) 687-7695
Principal Investigator: Deepa Subramaniam
Phone: 202-444-2144
Georgetown University Medical Center Georgetown University Medical Center is committed to excellence in research, education...
Click here to add this to my saved trials